Navigation Links
Video: GlaxoSmithKline Consumer Healthcare Offers Free Nicotine Lozenges for All Certified Pilots and Air Traffic Controllers to Help Them Safely Quit Smoking
Date:5/23/2008

SHES.

About the Commit Lozenge

Commit is approved by the FDA to help control tough cravings associated with quitting smoking(4). Commit has a unique dosage selector based on how soon a smoker smokes his first cigarette in the morning, so he can choose the strength that's right for him. The Commit lozenge helps people stop smoking by providing low, safe doses of NRT to ease withdrawal from cigarettes. Commit comes in different strengths -- 2 mg or 4 mg -- to be used depending on how soon a smoker has his first cigarette in the morning. The 2 mg dosage is for smokers who usually have their first cigarette more than thirty minutes after waking up. The 4 mg dosage is for smokers who usually have their first cigarette within thirty minutes of waking up.

About GlaxoSmithKline Consumer Healthcare

GSK Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. GSK offers the widest range of proven NRT products available, products which can significantly improve a smoker's chance of quitting successfully and have helped millions of people quit smoking. In addition, GSK offers several resources and support services designed specifically to help smokers and non-smokers understand and address the two components to smoking cessation: nicotine addiction and habit change. Its more than 30 well-known brands include the leading smoking cessation products, Nicorette(R), NicoDerm(R) CQ and Commit(R) as well as many medicine cabinet staples, including Abreva(R), alli(R) Aquafresh(R), Sensodyne(R), Tums(R) and Breathe Right(R), trademarks owned and/or licensed to GlaxoSmithKline Group of Companies.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and consumer healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

1. GSK Data on file, Study S254
'/>"/>

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2008)...10 don,t do enough to protect themselves from stro...HealthDay News) -- It,s one of medicine,s mantras:...lower it will have a dramatic impact on your risk ...cent of people with high blood pressure still aren...ng to a U.S. Centers for Disease Control and Preve...
(Date:11/21/2008)...UNTY, Calif., Nov. 21 Album Creati...irm, launches a new program offering big brand mar...aken the large, expensive ad agency process and se... a very hands-on approach," says Matt Parker, Crea... combines experience and proven brand-building tec...
(Date:11/21/2008)...HASSEE, Fla. -- A Florida State University College...s discovered an important new layer of regulation ...greater understanding of the way cancer begins. ,...ces at the College of Medicine, said the findings ...r and could lead to the design of new drugs that k...
(Date:11/21/2008)...riz., Nov. 21 The Provid...announced that Craig A. Norris, the Company,s,Chi...mpany,s Board of,Directors. Mr. Norris, appointm...gnation of Steven I. Geringer and returns the boar...ny committee of the Board. , Mr. Norris, ag...
Breaking Medicine News(10 mins):Health News:High Blood Pressure Stalks Many Americans 2Health News:High Blood Pressure Stalks Many Americans 3Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3
...nt positive side too, a study now reports. Bad gos...the study says that it may create or increase inti...in the June issue of the journal Personal Relation...egative attitudes that are frequently shared among...
...p of leading global health experts have come toget...ional donors// to negotiate affordable pricing of ...s of developing world countries and their partners...works and begin preparations for pneumococcal vacc...
...g of the American Society of Hypertension in New Y...e sexual dysfunction// (FSD) and high blood pressu...women with increased hypertension and increased ag...defined as persistent or recurring decrease in sex...
...brand new internet-based television show//: Pharma...PharmaVentures, says, ‘This show, the first in a m...eutical and biotechnology sectors with insightful ... transactions and industry trends. It gives exclus...
Other Medicine News:Health News:Intro of Pneumococcal Vaccines: Experts Urge Commitment From Industry 2Health News:Intro of Pneumococcal Vaccines: Experts Urge Commitment From Industry 3Health News:Link Established Between FSD and High Blood Pressure 2Health News:PharmaVentures Exploits Fastest Growing Media Channel to Launch First Pharmaceutical Business Television Show 2
(Date:11/20/2008)... Epeius Biotechnologies,announced today the resul...motherapy-resistant metastatic soft tissue sarcoma...awla, principal investigator, at the CTOS 14th,an... 2008. Patients received,repeated infusions of Re...of,safety and efficacy data showed no major toxic...
(Date:11/20/2008)...HASE III TRIAL SHOW SIGNIFICANT, DECREASES IN...ON, IN, FIBROMYALGIA P...lgium, Nov. 20 /PRNewswire-FirstCall/,-- Jazz Pha...next Brussels: UCB),announced today positive prel...ase III pivotal clinical trials of sodium oxybate ...
(Date:11/20/2008)...Call/ -- Duska Therapeutics,Inc., (OTC Bulletin ...d its,pivotal Phase 3 ATPace clinical trial proto...t (SPA) procedure with the U.S. Food and Drug Admi... agreement with the FDA, Duska intends to initiate...trolled and randomized Phase 3,clinical trial wit...
(Date:11/20/2008).../ -- The Scandinavian-based drug,development comp...es on its,lead antimicrobial candidate LTX-109. P...showed that the novel lytic peptidomimetic has an ...etter towards killing Staphylococcus,aureus and S...drugs. In,addition to this it has proven effectiv...
Breaking Medicine Technology:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2CellCyte Genetics Corp Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3175 1CellCyte Genetics Corp Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3175 2CellCyte Genetics Corp Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases 3175 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 1AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 2AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 3AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy 28TM 29 Bipolar Ablation System to Treat Atrial Fibrillatio 3172 4MGT Capital Investments Inc Announces Subsidiarys Preliminary Agreement to Acquire Maydeal com 11485 1MGT Capital Investments Inc Announces Subsidiarys Preliminary Agreement to Acquire Maydeal com 11485 2HLTH Corporation Update 11482 1HLTH Corporation Update 11482 2HLTH Corporation Update 11482 3HLTH Corporation Update 11482 4HLTH Corporation Update 11482 5HLTH Corporation Update 11482 6HLTH Corporation Update 11482 7HLTH Corporation Update 11482 8HLTH Corporation Update 11482 9HLTH Corporation Update 11482 10HLTH Corporation Update 11482 11HLTH Corporation Update 11482 12HLTH Corporation Update 11482 13
...HE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 27, 2007...ny involved in the,development and commercializati...ns at the 5th International Society for Stem Cell,...and, Australia,from June 17-20 and at the 13th Ann...lar Therapy (ISCT) in Sydney, Australia from June,...
...EW YORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S... both clinical and preclinical,data that support t...sm of action of Defibrotide in combination with an...s presented both an update,from the Company,s ongo...fractory or relapsed multiple myeloma with Defibro...
Other Medicine Technology:Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 2Opexa Advances Monocyte Derived Islet Technology to Proof of,Principle in stz-induced NOD/SCID Mice 3Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3
Supplied sterile in peel-open packages. Intended for one-time use.
Used when establishing a percutaneous tract for nephrostomy drainage. The wire guide has an extra stiff shaft and a gradual transition to a very flexible tip. Supplied sterile in peel-open packages.
Supplied sterile in peel-open packages. Intended for one-time use.
Supplied sterile in peel-open packages. Intended for one-time use.
Medicine Products: